Kingdon Capital Management’s Acceleron Pharma XLRN Stock Holding History

Kingdon Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-65,000	Closed	-$8.16M	–	86
2021 Q2	$8.16M	Buy	+65,000	New	+$8.2M	0.95%	38
2021 Q1	–	Sell	-15,000	Closed	-$1.92M	–	79
2020 Q4	$1.92M	Sell	15,000 -229,249	-94%	-$26.9M	0.21%	54
2020 Q3	$27.5M	Sell	244,249 -13,000	-5%	-$1.29M	3.09%	10
2020 Q2	$24.5M	Buy	257,249 +46,211	+22%	+$4.45M	2.23%	10
2020 Q1	$19M	Buy	+211,038	New	+$16.4M	3.47%	6

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Kingdon Capital Management's XLRN Position: Q3 2021 in Review

Kingdon Capital Management sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 65,000 shares — an estimated $8.16M sold.

Kingdon Capital Management first reported a position in XLRN in Q1 2020 and held it in 5 quarters. The position peaked at $27.5M in Q3 2020. 331 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Kingdon Capital Management reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Kingdon Capital Management sold 65,000 Acceleron Pharma shares in Q3 2021, an estimated $8.16M.
Kingdon Capital Management first reported a position in Acceleron Pharma in Q1 2020 and held it in 5 quarters.
Kingdon Capital Management's Acceleron Pharma position peaked at $27.5M in Q3 2020.
331 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Kingdon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.